SAN DIEGO, Nov. 25, 2019 /PRNewswire/ -- Shareholder
rights law firm Johnson Fistel, LLP has launched an investigation
into whether the board members of The Medicines Company (NASDAQ:
MDCO) breached their fiduciary duties in connection with the
proposed sale of the Company to Novartis AG.
On November 25, 2019, The
Medicines Company announced that it had signed a definitive merger
agreement with Novartis AG. Under the terms of the deal, The
Medicines Company stockholders will receive $85 per share in cash.
The investigation concerns whether The Medicines Company board
failed to satisfy its duties to the Company shareholders, including
whether the board adequately pursued alternatives to the
acquisition and whether the board obtained the best price possible
for The Medicines Company shares of common stock. Nationally
recognized Johnson Fistel is
investigating whether the proposed deal represents adequate
consideration, especially given that one Wall Street analyst has a
$100.00 price target on the
stock.
If you are a shareholder of The Medicines Company and
believe the proposed buyout price is too low or you're interested
in learning more about the investigation or your legal rights and
remedies, please contact lead analyst Jim
Baker (jimb@johnsonfistel.com) at
619-814-4471. If emailing, please include a
phone number.
Additionally, you can [Click here to join this action].
There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
https://www.johnsonfistel.com. Attorney advertising. Past results
do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[Click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/mdco-alert-johnson-fistel-investigates-proposed-sale-of-the-medicines-company-is-85-a-fair-price-300964556.html
SOURCE Johnson Fistel, LLP